Member Profile

Medigen Vaccine Biologics Corporation (also known as MVC) is a biopharmaceutical company focusing on the development and production of vaccines and biologics to prevent regional infectious diseases. MVC established Taiwan’s first cell-based vaccines and biologics manufacturing facility with PIC/S GMP certificate which located in Hsinchu Biomedical Science Park. The vaccine facility equipped with biosafety level 2+ production line, R&D lab, aseptic fill-finish line, QC and QA systems. With cell-culture technology, MVC also expands into cell therapy and is constructing a large cell preparation center (CPC). MVC has established a foothold in Taiwan and given priority to developing innovative pharmaceutical products for unmet medical needs. Meanwhile, MVC is dedicated to not only becoming the vaccine development and supply hub of the Asia-Pacific region but also protecting human health globally from the threats of various diseases.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2016 MVC partners with WHO/ UCAB to develop biosimilar Palivizumab
   2016 MVC obtains the US NIH’s authorization to develop Dengue Vaccine in 17 Countries and then expands license agreement to 26 countries and gets TFDA IND approval for phase 2 POC clinical trial.
   2016 MVC inaugurates Taiwan’s first cell-based vaccine manufacturing plant in Hsinchu Biomedical Science Park
   2018 MVC completes the phase 3 clinical trial patient enrollment of Quadrivalent Influenza Vaccine
   2019 MVC obtains PIC/S GMP Certificate of EV71 vaccine bulk production and aseptic filling/finishing
   2019 MVC enters strategic cell therapy alliance with MBC and TaiwanBio Therapeutics
   2019 MVC obtains EV71 vaccine phase 3 MRCT IND approval in Taiwan and Vietnam, and starts the patient enrollment in Taiwan
   2020 MVC obtains the US NIH’s global authorization to develop COVID-19 vaccine.
   2021 MVC initiated phase I trial for COVID-19 vaccine.
   2021 MVC initiated phase II trial for COVID-19 vaccine.
   2021 MVC successfully unblinded the results of phase II trial for COVID-19 vaccine and is applying for emergency use authorization (EUA).
   2021 MVC successfully unblinded the results of phase III trial for EV71 vaccine and is applying for drug license.